source
- Regeneron's LAG-3 inhibitor fianlimab fails Phase 3 skin cancer trialRegeneron announced that its experimental LAG-3 inhibitor fianlimab did not meet its primary endpoint in a late-stage trial for a skin cancer indication. The Phase 3 study was designed to evaluate…
- Pharma firms turn to outsourcing to boost value of aging drug portfoliosFor many years pharma companies treated legacy brands as low-maintenance cash generators, focusing only on steady but declining revenue once patents expired. With the largest patent cliff in histo…